Lithuanian medtech Sentante secures €6M in a Seed round led by Practica Capital
Summary
This innovation bears profound significance, particularly in critical cases such as stroke and heart attacks, which involve over six million procedures annually, where each passing minute significantly impacts the chances of a good outcome.We are thrilled to partner with Sentante, a company that aligns perfectly with our philosophy of supporting transformative innovations. With its unique teleoperated endovascular intervention system, Sentante is set to redefine surgical practices globally, improving both patient outcomes and the well-being of medical professionals. This investment underscores our commitment to advancing healthcare technologies that have the potential to create a significant, positive impact worldwide, Practica Capital is the lead investor in the company. To date, the firm made over 60 investments, including great companies like Atrandi, Oxipit, Biomatter Designs, PVcase, and others. It is an EU-backed agnostic fund investing across all technologies and verticals, and all EU countries.The company will use the proceeds from the financing for the planned clinical trial of the Sentante robotic system and preparation of commercial launch in targeted international markets.